Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer
Fluzoparib combined with Camrelizumab for maintenance treatment of locally advanced non-small cell lung cancer after concurrent radiotherapy and chemotherapy
Non-small Cell Lung Cancer
BIOLOGICAL: Camrelizumab|DRUG: Fluzoparib|DRUG: Cisplatin，Pemetrexed|DRUG: Cisplatin，Etoposide|DRUG: Carboplatin, Albumin Paclitaxel|RADIATION: Radiotherapy
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review, PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first., 2 year
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review, ORR is defined as the percentage of participants who have achieved a Complete Response (CR) or a Partial Response (PR), 2 year|Disease control rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review, Disease control rate is the proportion of patients whose tumors have shrunk or stabilized for a certain period of time, including complete remission (CR), partial remission (PR) and stable (SD) cases, 2 year|Overall Survival (OS), OS was defined as the time from randomization to death due to any cause. OS is presented. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis., 2 year|Safety of drug application, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 2 year
Fluzoparib combined with Camrelizumab for maintenance treatment of locally advanced non-small cell lung cancer after concurrent radiotherapy and chemotherapy